Licochalcone D directly targets JAK2 to induced apoptosis in human oral squamous cell carcinoma.
Animals
Antineoplastic Agents, Phytogenic
/ pharmacology
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Chalcones
/ pharmacology
Humans
Janus Kinase 2
/ antagonists & inhibitors
Janus Kinase Inhibitors
/ pharmacology
Male
Mice, Inbred BALB C
Mice, Nude
Mitochondria
/ drug effects
Molecular Targeted Therapy
Mouth Neoplasms
/ drug therapy
Signal Transduction
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Tumor Burden
/ drug effects
Xenograft Model Antitumor Assays
JAK2
STAT3
apoptosis
licochalcone (LC) D
mitochondrial membrane potential (MMP)
oral squamous cell carcinoma (OSCC)
reactive oxygen species (ROS)
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
18
04
2018
accepted:
26
06
2018
pubmed:
3
8
2018
medline:
18
12
2019
entrez:
3
8
2018
Statut:
ppublish
Résumé
Licochalcone (LC) families have been reported to have a wide range of biological function such as antioxidant, antibacterial, antiviral, and anticancer effects. Although various beneficial effects of LCD were revealed, its anticancer effect in human oral squamous cancer has not been identified. To examine the signaling pathway of LCD's anticancer effect, we determined whether LCD has physical interaction with Janus kinase (JAK2)/signal transducer and activator of transcription-3 (STAT3) signaling, which is critical in promoting cancer cell survival and proliferation. Our results demonstrated that LCD inhibited the kinase activity of JAK2, soft agar colony formation, and the proliferation of HN22 and HSC4 cells. LCD also induced mitochondrial apoptotic events such as altered mitochondrial membrane potential and reactive oxygen species production. LCD increased the expression of apoptosis-associated proteins in oral squamous cell carcinoma (OSCC) cells. Finally, the xenograft study showed that LCD significantly inhibited HN22 tumor growth. Immunohistochemical data supported that LCD suppressed p-JAK2 and p-STAT3 expression and induced cleaved-caspase-3 expression. These results indicate that the anticancer effect of LCD is due to the direct targeting of JAK2 kinase. Therefore, LCD can be used for therapeutic application against OSCC.
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Chalcones
0
Janus Kinase Inhibitors
0
licochalcone D
3P0SH94V09
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1780-1793Informations de copyright
© 2018 Wiley Periodicals, Inc.